相关实验视频
Updated: Sep 10, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
新的名字,新药物,在脂肪性肝病中更好的结果
Matthew Peverelle1, Mzamo Mbelle1, Deepak Joshi1
1Institute of Liver Studies, King's College Hospital, London, UK.
与代谢功能障碍相关的脂肪性肝病 (MASLD) 是一个越来越令人担忧的疾病. 包括GLP-1RA和THR-β激动剂在内的新疗法在治疗MASLD和与代谢功能失调相关的脂肪肝炎 (MASH) 中具有前景.
科学领域:
- 肝病和代谢疾病
- 胃肠病学
- 药理学
背景情况:
- 脂肪性肝病 (SLD),以前称为NAFLD/NASH,现在被称为MASLD/MASH,反映了它与代谢综合征的联系.
- 这种疾病影响到英国20%的成年人,是慢性肝病的主要原因,肝硬化和HCC的发病率正在上升.
- 直到最近, 针对MASLD的有效治疗方法是有限的.
研究的目的:
- 要总结脂肪性肝病的命名变化.
- 更新英国的MASLD和MASH负担.
- 审查MASLD的新兴治疗策略.
主要方法:
- 对新型MASLD疗法的最新临床试验数据的审查.
- 对英国SLD流行情况的当前流行病学数据的分析.
- 综合有关编号更新和处理进展的信息.
主要成果:
- 新的药物如GLP-1RA,resmetirom (THR-β激活剂) 和FGF21激活剂在逆转MASH和纤维化方面表现出潜力.
- GLP- 1 RAs在减肥方面表现出有效性,这是MASLD治疗的关键因素.
- 这些疗法为MASH患者提供了有前途的组织学改善.
结论:
- 在英国,MASLD是一个重要且日益严重的公共卫生问题.
- 新兴药物类代表了对MASLD/MASH的潜在疾病修饰治疗方法.
- 早期诊断和新的治疗措施对于治疗这种疾病至关重要.
更多相关视频
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
相关概念视频
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Hepatic Drug Excretion: Influencing Factors